Searchable abstracts of presentations at key conferences in endocrinology

ea0011p497 | Endocrine tumours and neoplasia | ECE2006

Differential expression of neurogenins by human pituitary adenomas

Fratticci A , Padronetti R , Giangaspero F , Ventura L , Piccirilli M , Esposito V , Gulino A , Alesse E , Jaffrain-Rea ML

The beta-HLH transcription factors NeuroD1 and ASH1 are frequently expressed by pituitary adenomas, both being present in all corticotroph, most clinically non-secreting (CNS) and a subset of GH and/or PRL-secreting adenomas. We wished to investigate the expression of the related beta-HLH factors neurogenins (Ngn) 1, 2 and 3 in the pituitary (n=4) and in a series of pituitary adenomas (n=45). RT-PCR was performed at different amplification cycles (up to 45) in al...

ea0029p1343 | Pituitary Basic | ICEECE2012

Aryl hydrocarbon receptor interacting protein in somatotroph adenomas: a molecular target for somatostatin analogues?

Jaffrain-Rea M. , Angelini M. , Occhi G. , Turchi A. , Castermans E. , Ceccato F. , Arcella A. , Esposito V. , Giangaspero F. , Pennelli G. , Daly A. , Alesse E. , Scaroni C. , Beckers A.

The aryl hydrocarbon receptor interacting protein (AIP) gene is abundantly expressed in normal somatotrophs. Somatotropinomas in patients with germline AIP mutations (AIPmut) are typically more aggressive than non-AIPmut adenomas and associated with higher GH/IGF1 secretion. AIP downregulation may also occur in sporadic somatotropinomas, especially in invasive tumours. We wished to evaluate the impact of somatostatin analogues (SSA) pre-treatment on AIP expression in sporadic ...